F S&P 500
5,072.75 +26.25 (+0.52%) F Dow Jones
38,225.00 +156.00 (+0.41%) F Nasdaq
17,553.00 +114.75 (+0.66%) E-mini Russell 2000 Index Futur
2,006.60 +16.90 (+0.85%) Petróleo
79.51 +0.51 (+0.65%) Oro
2,326.10 +15.10 (+0.65%)
bluebird bio, Inc. (BLUE)
Fuera de horario:
bluebird bio, Inc.
455 Grand Union Boulevard
Somerville, MA 02145
United States
339 499 9300
https://www.bluebirdbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 323
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Andrew Obenshain | President, CEO & Director | 1.04M | N/D | 1974 |
| Mr. Thomas J. Klima | Chief Commercial Officer & COO | 654.97k | N/D | 1972 |
| Mr. Richard A. Colvin M.D., Ph.D. | Chief Medical Officer | 696.24k | N/D | 1966 |
| Mr. Christopher Krawtschuk CPA | CFO, Principal Accounting Officer & Treasurer | N/D | N/D | 1974 |
| Mr. Joseph D. Vittiglio Esq., J.D. | Chief Legal & Business Officer and Secretary | N/D | N/D | 1972 |
| Jess Rowlands | Head of Corporate Communications | N/D | N/D | N/D |
| Ms. Andrea Walton | Chief People Officer | N/D | N/D | N/D |
| Mr. Kasra Kasraian | Senior Vice President of Technical Development & Operations | N/D | N/D | N/D |
| Mr. Scott Shoemaker | Senior Vice President of Quality | N/D | N/D | N/D |
| Ms. Sarah Alspach | Senior Vice President of External Affairs | N/D | N/D | N/D |
Descripción
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de bluebird bio, Inc. a partir del 29 de abril de 2024 es 4. Las puntuaciones principales son Auditoría: 3; Junta: 3; Derechos del accionista: 5; Compensación: 5.
